Addex Therapeutics Ltd (ADXN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has a cash flow conversion efficiency ratio of -0.128x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-608.40K) by net assets ($4.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ADXN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Addex Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Addex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Addex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Addex Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prima Globalindo Logistik Tbk
JK:PPGL
|
0.060x |
|
American Uranium Ltd
AU:AMU
|
-0.035x |
|
WebRock Ventures AB
ST:WRV
|
-0.007x |
|
Uni-Fuels Holdings Limited Class A Ordinary Shares
NASDAQ:UFG
|
-0.370x |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
-0.106x |
|
SunLink Health Systems Inc
NYSE MKT:SSY
|
-0.190x |
|
Mex Polska S.A.
WAR:MEX
|
0.244x |
|
NINE MILE METALS LTD
F:KQ9
|
-0.097x |
Annual Cash Flow Conversion Efficiency for Addex Therapeutics Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Addex Therapeutics Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.77 Million | $-2.08 Million | -0.435x | +21.58% |
| 2024-12-31 | $9.68 Million | $-5.37 Million | -0.555x | +92.04% |
| 2023-12-31 | $1.15 Million | $-7.99 Million | -6.977x | -108.55% |
| 2022-12-31 | $4.91 Million | $-16.44 Million | -3.346x | -285.22% |
| 2021-12-31 | $16.93 Million | $-14.71 Million | -0.869x | -4.18% |
| 2020-12-31 | $14.61 Million | $-12.18 Million | -0.834x | -124.41% |
| 2019-12-31 | $25.52 Million | $-9.48 Million | -0.372x | -932.20% |
| 2018-12-31 | $39.24 Million | $1.75 Million | 0.045x | +102.81% |
| 2017-12-31 | $1.34 Million | $-2.13 Million | -1.590x | +87.10% |
| 2016-12-31 | $218.59K | $-2.69 Million | -12.326x | -680.44% |
| 2015-12-31 | $1.66 Million | $-2.63 Million | -1.579x | -105.86% |
| 2014-12-31 | $2.35 Million | $-1.80 Million | -0.767x | +85.28% |
| 2013-12-31 | $3.03 Million | $-15.78 Million | -5.214x | -188.38% |
| 2012-12-31 | $16.29 Million | $-29.45 Million | -1.808x | -130.40% |
| 2011-12-31 | $33.84 Million | $-26.55 Million | -0.785x | -61.27% |
| 2010-12-31 | $64.41 Million | $-31.34 Million | -0.487x | +4.14% |
| 2009-12-31 | $77.58 Million | $-39.38 Million | -0.508x | -239.45% |
| 2008-12-31 | $118.99 Million | $-17.79 Million | -0.150x | +36.53% |
| 2007-12-31 | $140.11 Million | $-33.00 Million | -0.236x | +49.08% |
| 2006-12-31 | $42.28 Million | $-19.56 Million | -0.463x | -- |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more